Department of Clinical Sciences, College of Dentistry, Ajman University, United Arab Emirates; Center of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
Paediatric Dentistry, Faculty of Dentistry, The University of Hong Kong, Hong Kong; Dental Biomaterials, Faculty of Dental Medicine Al-Azhar University, Cairo, Egypt.
J Dent. 2023 Jan;128:104356. doi: 10.1016/j.jdent.2022.104356. Epub 2022 Nov 9.
OBJECTIVE(S): The objectives of the present study were to examine the - a) enamel remineralization potential of synbiotic-fluoride (SF) therapy using a multi-species bacterial pH-cycling model; and b) cytotoxic and genotoxic effects of SF therapy extracts.
The SF therapy group comprised of 2% arginine (Arg), 0.2% NaF, and a probiotic Lactobacillus rhamnosus GG (LRG). The intervention groups studied were: 1) No treatment; 2) 2% Arg; 3) 0.2% NaF; 4) LRG; 5) 2% Arg+0.2% NaF; 6) 2% Arg+LRG; 7) 0.2% NaF+LRG; and 8) 2% Arg+0.2% NaF+LRG (SF therapy). The enamel remineralization potential of SF therapy was investigated under cariogenic biofilm challenge; while the cytotoxicity and genotoxicity of SF therapy extracts were examined on HGF-1 and Chinese hamster fibroblast V79, respectively. To determine the remineralization effect, the specimens were subjected to mineral density (MD) assessment using micro-CT, Ca/P molar ratio with SEM-EDX, and enamel fluoride uptake (EFU) estimates. The HGF-1 proliferation assessment was quantified using MTT/CCK-8 assays with qualitative analysis by nuclei staining Hoechst-based fluorescence imaging. The genotoxicity was determined by micronuclei formation test.
Mineral gain and %remineralization derived from MD assessment for the SF therapy were significantly higher than the other groups (p<0.05). The %ΔCa/P for the SF and 2% Arg+0.2% NaF were significantly higher than the other groups (p<0.05). The SF and 2% Arg+0.2% NaF groups had the highest EFU compared to the other groups (p<0.05). No significant difference in the %viable HGF-1 cells were observed between the treatment interventions and no treatment group (p>0.05). Compared to the EMS-positive control, the micronuclei formation for all the intervention groups was significantly lower (p<0.05), with no significant difference among the treatment groups (p>0.05).
The SF therapy enhanced enamel remineralization with no biocompatibility concerns.
With the enhanced enamel remineralization potential discerned in the present study, the SF therapy can be used as a promising caries-preventive agent targeted for high caries-risk individuals.
本研究的目的是：a）使用多物种细菌 pH 循环模型检查益生菌-氟化物（SF）治疗的 - 釉质再矿化潜力；b）SF 治疗提取物的细胞毒性和遗传毒性作用。
SF 治疗组包括 2%精氨酸（Arg）、0.2%氟化钠（NaF）和益生菌鼠李糖乳杆菌 GG（LRG）。研究的干预组为：1）无治疗；2）2%Arg；3）0.2%NaF；4）LRG；5）2%Arg+0.2%NaF；6）2%Arg+LRG；7）0.2%NaF+LRG；和 8）2%Arg+0.2%NaF+LRG（SF 治疗）。在致龋生物膜挑战下研究 SF 治疗的再矿化潜力；同时，使用 HGF-1 和中国仓鼠肺成纤维细胞 V79 分别检查 SF 治疗提取物的细胞毒性和遗传毒性。为了确定再矿化效果，使用微计算机断层扫描（micro-CT）评估标本的矿物质密度（MD）、SEM-EDX 的 Ca/P 摩尔比和釉质氟摄取量（EFU）估计值。使用 MTT/CCK-8 测定 HGF-1 增殖评估，并通过基于 Hoechst 的荧光成像的核染色定性分析进行定量分析。通过微核形成试验确定遗传毒性。
SF 治疗的 MD 评估得出的矿物质增益和再矿化百分比明显高于其他组（p<0.05）。SF 和 2%Arg+0.2%NaF 的%ΔCa/P 明显高于其他组（p<0.05）。SF 和 2%Arg+0.2%NaF 组与其他组相比，EFU 最高（p<0.05）。与治疗干预和无治疗组相比，HGF-1 细胞的存活率无显著差异（p>0.05）。与 EMS 阳性对照组相比，所有干预组的微核形成均明显降低（p<0.05），且治疗组之间无显著差异（p>0.05）。
SF 治疗增强了釉质再矿化，且无生物相容性问题。
鉴于本研究中观察到增强的釉质再矿化潜力，SF 治疗可作为一种有前途的针对高龋风险个体的防龋剂。
